title: Poor prognosis and limited therapeutic options in patients with Budd-Chiari syndrome and portal venous system thrombosis.
abstract: OBJECTIVE
  Therapeutic options in Budd-Chiari syndrome (BCS) are highly dependent on the site and extent of hepatic vein thrombosis. The aim of this study was to evaluate the effect of additional portal venous system thrombosis on the clinical presentation, treatment and outcome in patients with BCS.
  
  
  METHODS
  Clinical notes of 51 patients with BCS admitted to our centre were evaluated. We identified 13 patients (25%) with BCS and additional portal venous system thrombosis. Ten patients were female and three male with a mean age at presentation of 42 years (range 32-67).
  
  
  RESULTS
  An underlying haematological aetiology was identified in 10 of the 13 patients. Only four patients (31%) were anticoagulated before referral to our centre. In addition to hepatic vein thrombosis seven patients had portal vein thrombosis (PVT), three had PVT, splenic vein (SV) and superior mesenteric vein (SMV) thrombosis and three had either SV, SMV or inferior vean cava (IVC) thrombosis. The presentation was acute in three patients, subacute in six and chronic in four with a high incidence of encephalopathy (6/13; 46%). Treatment included liver transplantation (four), mesoatrial shunt (one) and balloon dilatation of hepatic veins (two). Six patients were treated medically as all other options were considered too risky or technically impossible. Nine of 13 patients (70%) died either after surgery or before any treatment could be instituted (median survival 1 month), compared to 14/38 (37%) in patients with isolated hepatic vein thrombosis (median survival 6.3 years).
  
  
  CONCLUSIONS
  We conclude that patients with BCS and portal venous system thrombosis constitute a unique group with limited therapeutic options and poor prognosis. The importance of early recognition and anticoagulation of patients with BCS is emphasized.
authors.affiliation: Liver and Hepatobiliary Unit, Queen Elizabeth Hospital, Birmingham, UK.
authors.forename: A E
authors.initials: AE
authors.lastname: Mahmoud
authors.forename: A S
authors.initials: AS
authors.lastname: Helmy
authors.forename: L
authors.initials: L
authors.lastname: Billingham
authors.forename: E
authors.initials: E
authors.lastname: Elias
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000714:Anastomosis, Surgical; D000925:Anticoagulants / Q000627:therapeutic use; D006502:Budd-Chiari Syndrome / Q000150:complications / Q000401:mortality / Q000628:therapy*; D002404:Catheterization; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D011168:Portal System; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D013924:Thrombophlebitis / Q000150:complications / Q000401:mortality / Q000628:therapy*
chemical_list: D000925:Anticoagulants